Loading... Please wait...
Electronics Industry Market Research and Knowledge Network
Turning Knowledge Into Opportunity !
Browse Research Reports By Category:
- Category
- Nanotechnology
- Nanobiotechnology - Global Strategic Business Report
Nanobiotechnology - Global Strategic Business Report
Price:
USD $4,450.00
ISBN/SKU #:
GIA-MCP1476
Research Group:
Global Industry Analysts
Date of Publication:
February 2011
Summary
This report analyzes the worldwide markets for Nanobiotechnology in US$ Million by the following technology segments - Nanomaterials (Solid Inorganic Nanoparticles, Nanocomposites, Nanostructured Materials & Membranes, Nanotubes and Fullerenes, & Other Nanomaterials), and Nanodevices/Tools. The report provides separate comprehensive analytics for the US, Japan, Europe, and Rest of World. Annual forecasts are provided for each region for the period of 2007 through 2015. Also, a seven-year historic analysis is provided for these markets. The report profiles 117 companies including many key and niche players worldwide such as Aduro BioTech, Arrowhead Research Corporation, Calando Pharmaceuticals, Inc., Unidym, Inc., Agilent Technologies Inc., Asklepios BioPharmaceutical Inc., Biosante Phosphate Pharmaceuticals, Inc., Celgene Corporation, Abraxis Bioscience, Inc., Elan Pharmaceuticals, Flamel Technologies, Inc., Gilead Sciences Inc., Life Technologies Corporation, BioTrove, Inc., NanoBio Corporation, Nanogen, Inc., Nanophase Technologies Corporation, pSivida Ltd., Sigma Aldrich Company, Starpharma Holdings Ltd., Dendritic Nanotechnologies, Inc., SkyePharma Pharmaceuticals, Unidym, Inc., and Zyvex Instruments LLC. Market data and analytics are derived from primary and secondary research. Company profiles are mostly extracted from URL research and reported select online sources.
TABLE OF CONTENTS
NANOBIOTECHNOLOGY MCP-1476
A GLOBAL STRATEGIC BUSINESS REPORT
CONTENTS
1. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS 1
Study Reliability and Reporting Limitations 1
Disclaimers 2
Data Interpretation & Reporting Level 3
Quantitative Techniques & Analytics 3
Product Definitions and Scope of Study 3
1. Nanomaterials 4
Solid Inorganic Nanoparticles 4
Nanocomposites 4
Nanostructured Materials and Membranes 4
Nanotubes and Fullerenes 4
Other Nanomaterials 4
Nanoshells 4
Nanohorns 5
Nanocapsules 5
2. Nanodevices/Tools 5
2. INDUSTRY OVERVIEW 6
A Curtain Raiser 6
Nanobiotechnology - The Next Big Thing 7
Nanotechnology & Biology Tie the Knot: “Two to Tango” 9
Where Conventional Molecular Science Falls Short Nanobio
Steps In 9
What’s The Obsession With Size? 9
Why Analysis at the Cellular Level is Important? 10
Lessons from Nature 10
Dawn Breaks On Nanobiotechnology 11
Table 1: Nanobiotechnology and Related Medical Applications
Market (2007): Percentage Share Breakdown of Activity
Distribution by Region and Organizational Set-Up (includes
corresponding Graph/Chart) 11
Table 2: Percentage Breakdown of Number of Nanotechnology
Companies in Healthcare Industry Worldwide by Region/Country
(2008) (includes corresponding Graph/Chart) 12
Table 3: Percentage Breakdown of Number of Nanotechnology
Companies in Healthcare Industry Worldwide by Type - Private
and Public Sector (2008) 12
Table 4: Percentage Breakdown of Number of Nanotechnology
Companies in Healthcare Industry Worldwide By Sector -
Therapeutics and Drug Delivery; Clinical Diagnostics; Drug
Discovery Tools and Biomedical Research; and Biomaterials and
Biomedical Implants (2008) (includes corresponding
Graph/Chart) 12
Table 5: Percentage Breakdown of Number of Nanotechnology
Companies in The field of Therapeutics and Drug Delivery
Worldwide by Area - Targeted Nanoparticles, Solubility &
Reformulation, Sustained Release, Blood Brain Barrier,
Nanomaterial Therapeutics and Others (2008) (includes
corresponding Graph/Chart) 13
Table 6: Percentage Breakdown of Number of Nanotechnology
Companies in the field Therapeutics Worldwide by Therapeutic
Area - Oncology, Infectious Diseases, Central Nervous System
Diseases, Nutraceuticals, Ophthalmology and Others (2008)
(includes corresponding Graph/Chart) 13
Table 7: Percentage Breakdown of Number of Nanotechnology
Companies in the field of Clinical Imaging and Diagnostics
Worldwide by Area - Tags and Probes; Imaging Agents;
Biosensors and Bio-detection; and Instruments (2008)
(includes corresponding Graph/Chart) 13
Demystifying the Intriguing World of Nanobiotech 13
A Meeting Place of Medicine’s Best Solutions 14
Nanobiotechnology Promises to Deliver Nanomedicine 16
Nanobiotechnology to Become Viable for All Drug Development
Stages 16
Nanobioproducts in R&D As of 2007 & 2008 17
List of Marketed Nanoparticle-Based Pharmaceutical Products
As of the Year 2007 18
Nanoparticles: The Foundation of Nanobiotechnology 18
Improved Optical Properties and Stability of Nanoparticles 19
Nanoemulsions 19
Diagnosis & Treatment of Cancer 20
The Promise of Nanobiotechnology 20
Biological Weaponries Against Diseases Come in Small Packages 20
Proffered Benefits of Nanobiotechnology 21
Opportunity & Beyond 22
Nanobiotechnology - Will it Live Up to the Expectations? 22
The Future of Nanobiotechnology: Shape of Things to Come 23
Nanobiotechnology: The Outer Limits 23
Futuristics: A Rumination 24
Nanobiotechnology In the Year 2015 24
Field of Nanodiagnostics 24
Field of Regenerative Medicine 24
Field of Targeted Drug Delivery 25
Conclusions 25
3. MARKET DYNAMICS 26
Nanotechnology in the Recent Economic Climate: A Review 26
Nanobio Feels the Pinch or Does It ?: A Closer Look 26
Outlook 27
Developing Countries to Rise Over the Horizon 27
Table 8: Global Nanobiotechnology Market (2007): Percentage
Share Breakdown of Investments by Region (includes
corresponding Graph/Chart) 28
Table 9: Worldwide Funding in Nanotechnology (2004 & 2009):
Percentage Breakdown of Value Investments by Country/Region:
A Comparison (includes corresponding Graph/Chart) 28
Nanomaterials & Nanoparticles Witness Robust Activity 28
Focus on Improved Performance to Bring New Manufacturing
Methods for Nanomaterials 29
Private & Public Companies to Step Up Funding on Nanotechnology 29
Table 10: Worldwide Government Funding in Nanotechnology
(2008-2015) (In US$ Billion) (includes corresponding
Graph/Chart) 30
Increasing Awareness on Technology to Drive Growth 30
Demand for Novel Products to Push Up Growth 30
Nano-Enabled Drug Discovery Holds Tremendous Potential 31
Consolidation Sharpens the Industry’s Edge 31
The Regulatory Framework Evolves with the Technology 31
Quantum Dot Patents Pose Legal Tangles 31
Miniaturized Liquid Handling Becomes Progressive 32
Trends in Nanotechnology Enabled Drug Delivery Systems 32
Robust Growth On Cards 32
Table 11: Global Nanotechnology-Enabled Drug Delivery
Systems Market (2015 (P)): Percentage Share Breakdown of
Nanoparticles, Dendrimers, Polymer Therapeutics and Other
Nanostructures (includes corresponding Graph/Chart) 33
Patent Expiries: A Key Driver 33
Nanotechnology Enabled Drug Delivery to Exhume Unused Drugs 34
4. INDUSTRY CHALLENGES & ISSUES 35
Challenges 35
Commercial Exploration: A Treacherous Voyage 36
Conventional Medicine to Contest Nanomedicine Adoption 36
Nanomaterials Use: Weighed Down with Toxicity Concerns 37
Production Issues Continue to Plague Nanobiotech Industry 38
Lack of De Facto Standards: A Challenge to Reckon With 38
Embroilment Over Ethical Issues 39
Social Relevance 40
Economic Relevance 41
5. INDUSTRY STRUCTURE 42
Industry Structure: A Quick Primer 42
A Dissection of Select Segments 42
Nanoparticles 42
Nanotubes and Fullerenes 43
Dendrimers 43
A Peek Into the Regulatory Framework 43
United States 44
Europe 44
A Closer Look at Regional Nano Efforts 44
United States: Unraveling the Country’s Edge 44
Table 12: Global Intellectual Property Rights in
Nanotechnology by Leading Countries (2007) 45
Europe: Hot On the Heels of the US 45
Germany 46
France 46
United Kingdom 46
Scandinavia 46
Japan: A Noteworthy Region 47
6. NANOBIO’S EPOCHAL STRIDES IN MODERN MEDICINE 48
A Primer 48
Impact on Drug Delivery Systems 48
Benefits Offered 50
Drug Encapsulation 50
High Level of Specificity 50
Increase in Drug Solubility and Uptake 50
Greater Usage Flexibility 51
Impact On Molecular Diagnostic Imaging 51
Seeing The Unseen 51
Impact On Pharmaceutical Drug Formulations 52
Impact On Therapeutics 53
Silver Nanoparticles as Effective Antimicrobial Agents 53
Modern Day Nanomedicine: A Current Scenario 54
Nanomedicine: The Cynosure of All Eyes 54
Drug Delivery Systems Epitomized by Nanomedicine 55
Targeted NanoDrug Delivery & Release 55
Active and Passive Targeting Mechanisms in Drug Delivery 56
Sustained and Pulsatile Release Mechanisms in Drug Delivery 56
A Peek Into Potential Nanobio Enabled Drug Carriers 56
Micelles 57
Liposomes 57
Dendrimers & Liquid Crystals 57
Nanoparticles 57
Polymeric Nanoparticles 58
Hydrogels 58
Molecularly Imprinted Polymers 58
Microelectromechanical Systems (MEMS) 58
Nanosuspensions 59
Fullerenes: A Platform for GenX Drug Delivery 59
Types of Nano-Based Drug Delivery Systems, Related
Materials, and Structures 60
Dynamics of Regenerative Medicine 60
Tissue Engineering and Restorations 61
Nanotechnology Enabled Diagnostics 62
Promised Path Breaking Applications in Molecular Diagnostics
& Imaging 62
In-Vitro Diagnostics 63
Nanoprobes & Implantable Devices in In-vivo Imaging 64
Nanocomposites in Molecular Labeling & Diagnostics 65
Laboratory-on-a-Chip - A Revolutionary Technology in
Biomolecular Detection 65
Biosensors - Heralding New Opportunities in Molecular
Diagnostics 66
Nanobiosensors - A New Approach to Diagnostics Testing 66
Despite Huge Potential Key Hurdles Remain in
Commercialization 67
Magnetic Nanoparticles for Imaging Applications in MRI 67
Dendrimers Promise Milestone Applications in MRI 67
Conclusions 68
Gauging the Real World Impact of Nanobiotech On Cancer: A Case
Study 68
Quantum Dots Cock a Snook at Traditional Anti-Body Labeling
Agents 69
Chemotherapeutic Reengineering & Gene Therapy: New Treatment
Regimes 69
Laboratory-on-chip (LOC): A Platform for Cancer Diagnosis 70
7. CONCEPTUAL OVERVIEW 71
Nanotechnology: An Introduction 71
A Revolution in the Making 71
Nanobiotechnology: An Exposition 72
Nanobiotechnology & Medicine 72
Nanobiotechnology & Biofuels 73
Global Nanobiotechnology Market (2005): Major Products 73
Global Nanobiotechnology Market (2005): Major Products Under
Development 74
Analysis of Major Technology Segments 74
Nanomaterials 74
Nanoparticles 75
Nanoparticles in Labeling or Bio Tagging 75
Nanoparticles as Biomarkers 76
Classification of Nanoparticles 76
Solid Nanoparticles 76
Solid Lipid Nanoparticles 76
Calcium Phosphate Nanoparticles 76
Dendrimers 77
Nanocomposites 77
Lamellar Nanocomposites 78
Nanostructured Materials and Membranes 78
Nanotubes and Fullerenes 78
Other Nanomaterials 79
Nanoshells 79
Nanohorns 79
Nanocapsules 79
Nanodevices 80
Nanotools 80
Select Nanotools 80
Atomic Force Microscopes 80
Hot Embossing Lithography 81
Dip-Pen Nanolithography 81
8. GLOBAL RESEARCH CENTERS AND INSTITUTIONS 82
Centre for Biologic Nanotechnology (USA) 82
Centre for Biological and Environmental Nanotechnology (USA) 82
Institute of Bioengineering and Nanotechnology (Singapore) 82
The Nanobiotechnology Center (USA) 83
The Tyndall National Institute (Ireland) 83
9. RECENT INDUSTRY ACTIVITY/PRODUCT LAUNCHES 84
IDEX Inks Deal to Acquire Microfluidics 84
NanoMech Takes Over Canano 84
Arrowhead Sells Unidym to Wisepower 84
MP Biomedicals Signs Agreement of Cooperation with Russian
Nanotechnology Corporation 85
Bruker Acquires AFM and OIM Segments from Veeco 85
Audax Inks an Agreement with Brown to Acquire Osteobiologic
Nanotechnology 85
Celgene Acquires Abraxis 86
ELITech Completes Assets Acquisition of Nanogen 86
Life Technologies Acquires BioTrove 86
GSK Inks License With NanoBio to Market NB-001 87
CPN Establishes New Medical Nanobiotechnology R&D Center 87
IBM to Setup New Research Center in Wroclaw 87
Life Technologies and Zymera Ink Licensing Deal for Quantum
Dots Technology 87
APR Acquires Nanotechnology Platform Technology for Preparing
Biotechnology Products 88
Lockheed Teams Up with IIT-Delhi for Nanobiotechnology Research 88
Piedmont Triad to Institute Statewide Nanobiotech Center 88
Biocon and Abraxis Introduce ABRAXANE in India 89
Starpharma Launches a Research Reagent Kit 89
Monash Enters Into a Deal with National Fabrication Facility
of Australia 90
Taiwan Inks Nanotechnology Collaboration Deal with Australia 90
Avanti Institutes New Targeted Drug Delivery Company, Chikujee
Therapeutics 90
CytoViva Rolls Out New Research Tool for Nanotechnology 91
Dabur Obtains DCGI Approval for Nanoxel in New Indications 91
Researchers Discover New Nanoparticles for Treating Brain
Infection 91
Capsulution Tests Nanoparticle-Based Drug Formulation for
Improved Bio-Availability 92
Invitrogen Signs Agreement with Genisphere 92
Sigma-Aldrich Signs Deal With Nanoco Technologies 93
Unidym Sells First License Option for Patent Portfolio to MDA 93
Unidym Spins Off Carbon Nanotubes Therapeutics Business into
Ensysce Biosciences 93
Nacalai USA and Nano-C Enter into Collaboration Agreement for
HPLC Technology 94
Advanced Materials Technology Obtains License for LBL®
Technology from Capsulution 94
Nanogen and The Elitech Group Announce Merger 94
NanoViricides Signs MCRADA Agreement with CDC for Rabies 95
Manhattan Scientifics Acquires Metallicum 95
HemCon Medical Technologies Acquires Alltracel Pharmaceuticals 95
CN Probes Inks Agreement With a Leading MEMS Foundry 96
PrimeGen Biotech LLC Enters into Corporate Alliance with Unidym 96
Ondine Acquires Exclusive License from UCL Business 96
Dabur Introduces Nanotechnology Based Anti-Cancer Drug
Delivery System - Nanoxel 96
Mitsui Ties Up With NIOSH to Evaluate Safety of Carbon Nanotubes 97
Unidym Merges with Carbon Nanotechnologies 97
10. FOCUS ON SELECT GLOBAL PLAYERS 98
Aduro BioTech (USA) 98
Arrowhead Research Corporation (USA) 98
Calando Pharmaceuticals, Inc. (USA) 98
Agilent Technologies Inc (USA) 99
Asklepios BioPharmaceutical Inc (USA) 99
Biosante Phosphate Pharmaceuticals, Inc. (USA) 99
Celgene Corporation (USA) 99
Abraxis Bioscience, Inc (USA) 100
Elan Pharmaceuticals, Inc. (USA) 100
Flamel Technologies, Inc. (France) 100
Gilead Sciences Inc (USA) 101
Life Technologies Corporation (USA) 101
BioTrove, Inc. (USA) 101
NanoBio Corporation (USA) 101
Nanogen, Inc. (US) 102
Nanophase Technologies Corporation (USA) 102
pSivida Ltd (Australia) 103
Sigma Aldrich Company (USA) 103
Starpharma Holdings Ltd. (Australia) 103
Dendritic Nanotechnologies, Inc. (USA) 104
SkyePharma Pharmaceuticals (UK) 104
Unidym, Inc. (USA) 105
Zyvex Instruments LLC (USA) 105
11. GLOBAL MARKET PERSPECTIVE 106
Table 13: World Recent Past, Current & Future Analysis for
Nanobiotechnology by Geographic Region - USA, Japan, Europe,
and Rest of World Markets Independently Analyzed with Annual
Revenue Figures in US$ Million for Years 2007 through 2015
(includes corresponding Graph/Chart) 106
Table 14: World Historic Review for Nanobiotechnology by
Geographic Region - USA, Japan, Europe, and Rest of World
Markets Independently Analyzed with Annual Revenue Figures in
US$ Million for Years 2001 through 2006 (includes
corresponding Graph/Chart) 107
Table 15: World 13-Year Perspective for Nanobiotechnology by
Geographic Region - Percentage Breakdown of Revenues for USA,
Japan, Europe, and Rest of World for Years 2003, 2009 & 2015
(includes corresponding Graph/Chart) 108
Analytics by Product Segment 109
Table 16: World Recent Past, Current & Future Analysis for
Nanomaterials by Geographic Region - USA, Japan, Europe, and
Rest of World Markets Independently Analyzed with Annual
Revenue Figures in US$ Million for Years 2007 through 2015
(includes corresponding Graph/Chart) 109
Table 17: World Historic Review for Nanomaterials by
Geographic Region - USA, Japan, Europe, and Rest of World
Markets Independently Analyzed with Annual Revenue Figures in
US$ Million for Years 2001 through 2006 (includes
corresponding Graph/Chart) 110
Table 18: World 13-Year Perspective for Nanomaterials by
Geographic Region - Percentage Breakdown of Revenues for USA,
Japan, Europe, and Rest of World for Years 2003, 2009 & 2015
(includes corresponding Graph/Chart) 111
Table 19: World Recent Past, Current & Future Analysis for
Solid Inorganic Nanoparticles by Geographic Region - USA,
Japan, Europe, and Rest of World Markets Independently
Analyzed with Annual Revenue Figures in US$ Million for Years
2007 through 2015 (includes corresponding Graph/Chart) 112
Table 20: World Historic Review for Solid Inorganic
Nanoparticles by Geographic Region - USA, Japan, Europe, and
Rest of World Markets Independently Analyzed with Annual
Revenue Figures in US$ Million for Years 2001 through 2006
(includes corresponding Graph/Chart) 113
Table 21: World 13-Year Perspective for Solid Inorganic
Nanoparticles by Geographic Region - Percentage Breakdown of
Revenues for USA, Japan, Europe, and Rest of World for Years
2003, 2009 & 2015 (includes corresponding Graph/Chart) 114
Table 22: World Recent Past, Current & Future Analysis for
Nanocomposites by Geographic Region - USA, Japan, Europe, and
Rest of World Markets Independently Analyzed with Annual
Revenue Figures in US$ Million for Years 2007 through 2015
(includes corresponding Graph/Chart) 115
Table 23: World Historic Review for Nanocomposites by
Geographic Region - USA, Japan, Europe, and Rest of World
Markets Independently Analyzed with Annual Revenue Figures in
US$ Million for Years 2001 through 2006 (includes
corresponding Graph/Chart) 116
Table 24: World 13-Year Perspective for Nanocomposites by
Geographic Region - Percentage Breakdown of Revenues for USA,
Japan, Europe, and Rest of World for Years 2003, 2009 & 2015
(includes corresponding Graph/Chart) 117
Table 25: World Recent Past, Current & Future Analysis for
Nanostructured Materials & Membranes by Geographic Region -
USA, Japan, Europe, and Rest of World Markets Independently
Analyzed with Annual Revenue Figures in US$ Million for Years
2007 through 2015 (includes corresponding Graph/Chart) 118
Table 26: World Historic Review for Nanostructured Materials &
Membranes by Geographic Region - USA, Japan, Europe, and Rest
of World Markets Independently Analyzed with Annual Revenue
Figures in US$ Million for Years 2001 through 2006 (includes
corresponding Graph/Chart) 119
Table 27: World 13-Year Perspective for Nanostructured
Materials & Membranes by Geographic Region - Percentage
Breakdown of Revenues for USA, Japan, Europe, and Rest of
World for Years 2003, 2009 & 2015 (includes corresponding
Graph/Chart) 120
Table 28: World Recent Past, Current & Future Analysis for
Nanotubes and Fullerenes by Geographic Region - USA, Japan,
Europe, and Rest of World Markets Independently Analyzed with
Annual Revenue Figures in US$ Million for Years 2007 through
2015 (includes corresponding Graph/Chart) 121
Table 29: World Historic Review for Nanotubes and Fullerenes
by Geographic Region - USA, Japan, Europe, and Rest of World
Markets Independently Analyzed with Annual Revenue Figures in
US$ Million for Years 2001 through 2006 (includes
corresponding Graph/Chart) 122
Table 30: World 13-Year Perspective for Nanotubes and
Fullerenes by Geographic Region - Percentage Breakdown of
Revenues for USA, Japan, Europe, and Rest of World for Years
2003, 2009 & 2015 (includes corresponding Graph/Chart) 123
Table 31: World Recent Past, Current & Future Analysis for
Other Nanomaterials by Geographic Region - USA, Japan, Europe,
and Rest of World Markets Independently Analyzed with Annual
Revenue Figures in US$ Million for Years 2007 through 2015
(includes corresponding Graph/Chart) 124
Table 32: World Historic Review for Other Nanomaterials by
Geographic Region - USA, Japan, Europe, and Rest of World
Markets Independently Analyzed with Annual Revenue Figures in
US$ Million for Years 2001 through 2006 (includes
corresponding Graph/Chart) 125
Table 33: World 13-Year Perspective for Other Nanomaterials by
Geographic Region - Percentage Breakdown of Revenues for USA,
Japan, Europe, and Rest of World for Years 2003, 2009 & 2015
(includes corresponding Graph/Chart) 126
Table 34: World Recent Past, Current & Future Analysis for
Nanodevices/Tools by Geographic Region - USA, Japan, Europe,
and Rest of World Markets Independently Analyzed with Annual
Revenue Figures in US$ Million for Years 2007 through 2015
(includes corresponding Graph/Chart) 127
Table 35: World Historic Review for Nanodevices/Tools by
Geographic Region - USA, Japan, Europe, and Rest of World
Markets Independently Analyzed with Annual Revenue Figures in
US$ Million for Years 2001 through 2006 (includes
corresponding Graph/Chart) 128
Table 36: World 13-Year Perspective for Nanodevices/Tools by
Geographic Region - Percentage Breakdown of Revenues for USA,
Japan, Europe, and Rest of World for Years 2003, 2009 & 2015
(includes corresponding Graph/Chart) 129
Analytics by Application 130
Table 37: World Recent Past, Current & Future Analysis for
Nanobiotechnology by Application - Pharmaceuticals, Medical
Devices, Medical Research and Others Independently Analyzed
with Annual Revenue Figures in US$ Million for Years 2007
through 2015 (includes corresponding Graph/Chart) 130
Table 38: World 9-Year Perspective for Nanobiotechnology by
Application - Percentage Breakdown of Revenues for
Pharmaceuticals, Medical Devices, Medical Research and Others
for Years 2007, 2009 & 2015 (includes corresponding
Graph/Chart) 131
12. THE UNITED STATES 132
A.Market Analysis 132
Outlook 132
Industry Overview 132
Public Sector Funding 132
Major Nanobiotechnology Institutions and Centers 133
The Nanobiotechnology Center (NBTC) 133
Key technological advances achieved by NBTC in recent years - 133
Principal NBTC Partners 133
Centre for Biologic Nanotechnology (CBN) 134
Centre for Biological and Environmental Nanotechnology (CBEN) 134
Regulatory Environment 135
B.Market Analytics 136
Table 39: US Recent Past, Current & Future Analysis for
Nanobiotechnology by Technology Segment - Nanomaterials
(Solid Inorganic Nanoparticles, Nanocomposites,
Nanostructured Materials & Membranes, Nanotubes and
Fullerenes, Other Nanomaterials) and Nanodevices/ Tools
Markets Independently Analyzed with Annual Revenue Figures
in US$ Million for Years 2007 through 2015 (includes
corresponding Graph/Chart) 136
Table 40: US Historic Review for Nanobiotechnology by
Technology Segment - Nanomaterials (Solid Inorganic
Nanoparticles, Nanocomposites, Nanostructured Materials &
Membranes, Nanotubes and Fullerenes, Other Nanomaterials)
and Nanodevices/ Tools Markets Independently Analyzed with
Annual Revenue Figures in US$ Million for Years 2001 through
2006 (includes corresponding Graph/Chart) 137
Table 41: US 13-Year Perspective for Nanobiotechnology by
Technology Segment -Percentage Breakdown of Revenues for
Nanomaterials (Solid Inorganic Nanoparticles,
Nanocomposites, Nanostructured Materials & Membranes,
Nanotubes and Fullerenes, Other Nanomaterials) and
Nanodevices/Tools for Years 2003, 2009 & 2015 (includes
corresponding Graph/Chart) 138
13. JAPAN 139
A.Market Analysis 139
Public Sector Funding 139
B.Market Analytics 140
Table 42: Japanese Recent Past, Current & Future Analysis
for Nanobiotechnology by Technology Segment - Nanomaterials
(Solid Inorganic Nanoparticles, Nanocomposites,
Nanostructured Materials & Membranes, Nanotubes and
Fullerenes, Other Nanomaterials) and Nanodevices/Tools
Markets Independently Analyzed with Annual Revenue Figures
in US$ Million for Years 2007 through 2015 (includes
corresponding Graph/Chart) 140
Table 43: Japanese Historic Review for Nanobiotechnology by
Technology Segment - Nanomaterials (Solid Inorganic
Nanoparticles, Nanocomposites, Nanostructured Materials &
Membranes, Nanotubes and Fullerenes, Other Nanomaterials)
and Nanodevices/ Tools Markets Independently Analyzed with
Annual Revenue Figures in US$ Million for Years 2001 through
2006 (includes corresponding Graph/Chart) 141
Table 44: Japanese 13-Year Perspective for Nanobiotechnology
by Technology Segment - Percentage Breakdown of Revenues for
Nanomaterials (Solid Inorganic Nanoparticles,
Nanocomposites, Nanostructured Materials & Membranes,
Nanotubes and Fullerenes, Other Nanomaterials) and
Nanodevices/Tools for Years 2003, 2009 & 2015 (includes
corresponding Graph/Chart) 142
14. EUROPE 143
A.Market Analysis 143
Outlook 143
Market Overview 143
European Union Banks Heavily on Nanobiotechnology 143
Nano2Life Network 144
Major Nanobiotechnology Networks in Europe as of the Year
2006 145
Public Sector Funding 145
Regulatory Environment 145
Registration for Novel Nanobiotech Drugs Pose Major Bottlenecks 146
Focus on Select Markets 146
Germany 146
France 146
United Kingdom 147
Russia 147
Russian Biotech Players Eye Partnerships with Indian
Counterparts 148
Rest of Europe 149
Ireland 149
Market Overview 149
Key Research Institutions/Centers in Nanobiotechnology 149
The Tyndall National Institute 149
The Centre for Research on Adaptive Nanostructures and
NanoDevices 150
The National Centre for Sensor Research 150
The Sami Nasr Institute for Advanced Materials Science 150
B.Market Analytics 151
Table 45: European Recent Past, Current & Future Analysis
for Nanobiotechnology by Technology Segment - Nanomaterials
(Solid Inorganic Nanoparticles, Nanocomposites,
Nanostructured Materials & Membranes, Nanotubes and
Fullerenes, Other Nanomaterials) and Nanodevices/Tools
Markets Independently Analyzed with Annual Revenue Figures
in US$ Million for Years 2007 through 2015 (includes
corresponding Graph/Chart) 151
Table 46: European Historic Review for Nanobiotechnology by
Technology Segment - Nanomaterials (Solid Inorganic
Nanoparticles, Nanocomposites, Nanostructured Materials &
Membranes, Nanotubes and Fullerenes, Other Nanomaterials)
and Nanodevices/ Tools Markets Independently Analyzed with
Annual Revenue Figures in US$ Million for Years 2001 through
2006 (includes corresponding Graph/Chart) 152
Table 47: European 13-Year Perspective for Nanobiotechnology
by Technology Segment - Percentage Breakdown of Revenues for
Nanomaterials (Solid Inorganic Nanoparticles,
Nanocomposites, Nanostructured Materials & Membranes,
Nanotubes and Fullerenes, Other Nanomaterials) and
Nanodevices/Tools for Years 2003 2009 & 2015 (includes
corresponding Graph/Chart) 153
15. REST OF WORLD 154
A.Market Analysis 154
Outlook 154
Public Sector Funding 154
Focus on Select Markets 154
Australia 154
Market Overview 154
Major Institutions 155
Commonwealth Scientific and Industrial Research
Organisation (CSIRO) 155
India 155
Market Overview 155
Government Takes Big Initiatives to Promote
Nanobiotechnology 156
Agriculture, Livestock Sectors to Warm Up to
Nanobiotechnology Benefits 156
Korea 156
Taiwan 157
Nanotechnology in Medicine - Small Yet Growing Segment in
Taiwan 158
Iran 158
B.Market Analytics 159
Table 48: Rest of World Recent Past, Current & Future
Analysis for Nanobiotechnology by Technology Segment -
Nanomaterials (Solid Inorganic Nanoparticles,
Nanocomposites, Nanostructured Materials & Membranes,
Nanotubes and Fullerenes, Other Nanomaterials) and
Nanodevices/Tools Markets Independently Analyzed with Annual
Revenue Figures in US$ Million for Years 2007 through 2015
(includes corresponding Graph/Chart) 159
Table 49: Rest of World Historic Review for
Nanobiotechnology by Technology Segment - Nanomaterials
(Solid Inorganic Nanoparticles, Nanocomposites,
Nanostructured Materials & Membranes, Nanotubes and
Fullerenes, Other Nanomaterials) and Nanodevices/ Tools
Markets Independently Analyzed with Annual Revenue Figures
in US$ Million for Years 2001 through 2006 (includes
corresponding Graph/Chart) 160
Table 50: Rest of World 13-Year Perspective for
Nanobiotechnology by Technology Segment - Percentage
Breakdown of Revenues for Nanomaterials (Solid Inorganic
Nanoparticles, Nanocomposites, Nanostructured Materials &
Membranes, Nanotubes and Fullerenes, Other Nanomaterials)
and Nanodevices/Tools for Years 2003, 2009 & 2015 (includes
corresponding Graph/Chart) 161
COMPETITIVE LANDSCAPE
Total Companies Profiled: 117 (including Divisions/Subsidiaries - 122)
------------------------------------------
Region/Country Players
------------------------------------------
The United States 75
Canada 2
Japan 1
Europe 32
France 3
Germany 8
The United Kingdom 9
Rest of Europe 12
Asia-Pacific (Excluding Japan) 9
Middle-East 3
------------------------------------------
Additional Information
Number of Pages: 642
This report is offered in PDF format via e-mail. Once downloaded, the PDF can’t be copied to another computer. The user is permitted to print one full copy of the report. Extra copies or licenses may be purchased at 10% of the list price.
This report is offered in PDF format via e-mail. Once downloaded, the PDF can’t be copied to another computer. The user is permitted to print one full copy of the report. Extra copies or licenses may be purchased at 10% of the list price.
Find Similar Products by Category
Customers Who Viewed This Product Also Viewed
-
USD $4,950.00
-
USD $12,700.00
-
USD $4,500.00
-
USD $4,500.00
Currency Converter
Choose a currency below to display product prices in the selected currency.
Add to Wish List
Related Products
-
Superconductors - Global Strategic Business Report USD $4,950.00
-
Routers - A Global Strategic Business Report USD $4,500.00
-
WiMAX - Global Strategic Business Report USD $4,500.00
-
3G/3.5G - Global Strategic Business Report USD $4,450.00
-
Sensors: A Global Strategic Business Report USD $4,950.00
You Recently Viewed...
All prices are in USD. Copyright 1997-2012 Electronics.ca Publications.
|
Electronics.ca™ is a global research network serving the industry, corporations and investment banks. |
